From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
• Funding for Companies Developing Innovative Technologies that Improve Molecular and Cellular Analysis of Cancer – November 4 deadline • 2013 HHS SBIR & STTR Omnibus Solicitations for Investigator-Initiated Projects – December 5 deadline • Funding for Innovative Health IT and Single-Cell Analysis Tools – December 5 deadlines • Before You […]
TGen-Scottsdale Healthcare research shows ability to do whole genome and whole transcriptome sequencing for patients with advanced cancers
Faster analysis of genetic variations should uncover new drug targets and pathways even as cancers mutate beyond initial therapies
TGen-led study links lack of SMG1 to protein aggregates associated with Parkinson’s disease, forms of dementia and multiple systems atrophy (MSA)
Simulation Technology Improves Medical Education, Creates Jobs
- iPain Summit 2020
- 11/12/2020 - 11/14/2020
- AZBioPEERS: Election 2020 & The Impact on Bio and Med Tech
- AZBio Trailblazer Awards and Legislator Appreciation Event
- AZBioPEERS: Getting Ready for JPM